| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.62 |
| 52 Week High | US$3.08 |
| 52 Week Low | US$1.21 |
| Beta | 1.3 |
| 1 Month Change | -13.37% |
| 3 Month Change | -13.83% |
| 1 Year Change | -28.95% |
| 3 Year Change | -73.59% |
| 5 Year Change | -70.76% |
| Change since IPO | -86.64% |
Recent News & Updates
Recent updates
Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt
Apr 12
Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company
Mar 07Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
Jan 18Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?
Oct 06Is Cerus (NASDAQ:CERS) A Risky Investment?
Jul 07Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
May 12Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)
Sep 29Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M
Aug 04Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside
Jul 14Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?
Jul 06Is Cerus (NASDAQ:CERS) Using Debt Sensibly?
Mar 17Cerus Corporation: Outperforming And Gaining Momentum
Jan 28Cerus (NASDAQ:CERS) Has Debt But No Earnings; Should You Worry?
Oct 30Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy
Sep 17Shareholder Returns
| CERS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.3% | 0.007% | 0.7% |
| 1Y | -28.9% | -1.0% | 23.9% |
Return vs Industry: CERS underperformed the US Medical Equipment industry which returned -1% over the past year.
Return vs Market: CERS underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| CERS volatility | |
|---|---|
| CERS Average Weekly Movement | 11.7% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CERS's share price has been volatile over the past 3 months.
Volatility Over Time: CERS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 631 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CERS fundamental statistics | |
|---|---|
| Market cap | US$299.52m |
| Earnings (TTM) | -US$31.56m |
| Revenue (TTM) | US$163.76m |
1.8x
P/S Ratio-9.5x
P/E RatioIs CERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERS income statement (TTM) | |
|---|---|
| Revenue | US$163.76m |
| Cost of Revenue | US$73.37m |
| Gross Profit | US$90.39m |
| Other Expenses | US$121.94m |
| Earnings | -US$31.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 55.19% |
| Net Profit Margin | -19.27% |
| Debt/Equity Ratio | 169.3% |
How did CERS perform over the long term?
See historical performance and comparison